- Home
- MBRX vs ENLV Comparison
MBRX vs ENLV Comparison
Compare MBRX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- ENLV
- Stock Information
- Founded
- MBRX 2015
- ENLV 2005
- Country
- MBRX United States
- ENLV Israel
- Employees
- MBRX N/A
- ENLV N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- MBRX Health Care
- ENLV Health Care
- Exchange
- MBRX Nasdaq
- ENLV Nasdaq
- Market Cap
- MBRX 23.5M
- ENLV 26.6M
- IPO Year
- MBRX 2016
- ENLV 1995
- Fundamental
- Price
- MBRX $0.43
- ENLV $1.06
- Analyst Decision
- MBRX Strong Buy
- ENLV Strong Buy
- Analyst Count
- MBRX 4
- ENLV 2
- Target Price
- MBRX $5.00
- ENLV $10.00
- AVG Volume (30 Days)
- MBRX 4.1M
- ENLV 192.6K
- Earning Date
- MBRX 11-12-2025
- ENLV 11-28-2025
- Dividend Yield
- MBRX N/A
- ENLV N/A
- EPS Growth
- MBRX N/A
- ENLV N/A
- EPS
- MBRX N/A
- ENLV N/A
- Revenue
- MBRX N/A
- ENLV N/A
- Revenue This Year
- MBRX N/A
- ENLV N/A
- Revenue Next Year
- MBRX N/A
- ENLV N/A
- P/E Ratio
- MBRX N/A
- ENLV N/A
- Revenue Growth
- MBRX N/A
- ENLV N/A
- 52 Week Low
- MBRX $0.25
- ENLV $0.81
- 52 Week High
- MBRX $3.65
- ENLV $2.10
- Technical
- Relative Strength Index (RSI)
- MBRX 41.91
- ENLV 42.91
- Support Level
- MBRX $0.46
- ENLV $1.03
- Resistance Level
- MBRX $0.54
- ENLV $1.16
- Average True Range (ATR)
- MBRX 0.04
- ENLV 0.05
- MACD
- MBRX -0.01
- ENLV -0.00
- Stochastic Oscillator
- MBRX 3.27
- ENLV 7.69
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.